Innovent Gains China Commercialization Rights for VANFLYTA

Company: Innovent Biologics · Event Type: Deal and Financing · Product/Asset: VANFLYTA · Subject: Acute Myeloid Leukemia · Event Date: August 9, 2026 Summary Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for commercialization of VANFLYTA (quizartinib) in China. Innovent will hold sole commercialization…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal